newsfilter
← Latest News
GlobeNewswire·

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat